Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vitamin O

This article was originally published in The Tan Sheet

Executive Summary

Two companies and their owner are permanently barred from making unsupported claims that Vitamin O prevents or effectively treats life-threatening conditions such as cancer, cardiovascular and pulmonary diseases, under an FTC consent order entered in Spokane, Wash. federal court April 28. Rose Creek Health Products, Staff of Life and Donald Smyth, president and sole shareholder of both firms, also are barred from claiming the supplement's effectiveness is established by medical or scientific research or studies unless they can substantiate those claims. The defendants will pay $375,000 in redress to settle an FTC lawsuit, filed in March 1999, alleging false and misleading advertising (1"The Tan Sheet" March 22, 1999, p. 6)

You may also be interested in...

Vitamin O Marketers Charged By FTC With "False And Misleading" Ad Claims

The Federal Trade Commission charges Rose Creek Health Products, The Staff of Life and Donald Smyth, owner of both entities, with violating the FTC Act for deceptively marketing its dietary supplement product Vitamin O in a complaint filed March 11 in Spokane, Wash. federal court.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts